MX2017013859A - Composiciones novedosas y metodos para inmunoterapias que comprenden adyuvantes del agonistas del ligando receptor de integrina de molecula pequeña. - Google Patents
Composiciones novedosas y metodos para inmunoterapias que comprenden adyuvantes del agonistas del ligando receptor de integrina de molecula pequeña.Info
- Publication number
- MX2017013859A MX2017013859A MX2017013859A MX2017013859A MX2017013859A MX 2017013859 A MX2017013859 A MX 2017013859A MX 2017013859 A MX2017013859 A MX 2017013859A MX 2017013859 A MX2017013859 A MX 2017013859A MX 2017013859 A MX2017013859 A MX 2017013859A
- Authority
- MX
- Mexico
- Prior art keywords
- immunotherapies
- limited
- integrin
- small molecule
- cell
- Prior art date
Links
- 102000006495 integrins Human genes 0.000 title abstract 4
- 108010044426 integrins Proteins 0.000 title abstract 4
- 239000003446 ligand Substances 0.000 title abstract 4
- 238000009169 immunotherapy Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000003384 small molecules Chemical class 0.000 title abstract 2
- 239000002671 adjuvant Substances 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 238000011467 adoptive cell therapy Methods 0.000 abstract 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 2
- 239000012636 effector Substances 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 abstract 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 abstract 1
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000030741 antigen processing and presentation Effects 0.000 abstract 1
- 238000001815 biotherapy Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 230000022534 cell killing Effects 0.000 abstract 1
- 230000001461 cytolytic effect Effects 0.000 abstract 1
- 230000008611 intercellular interaction Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000037452 priming Effects 0.000 abstract 1
- 210000000225 synapse Anatomy 0.000 abstract 1
- 229960000575 trastuzumab Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C1/00—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cell Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Los mimóticos del ligando de integrina de molócula pequeña facilitan las interacciones del ligando de integrina, los cuales se pueden utilizar para preparar vacunas, terapias de cólulas adoptivas, inmunoterapias para el cáncer, y una variedad de otras condiciones. Ya que las interacciones de cólula-cólula mediadas por integrina son decisivas para la presentación de antígenos y el exterminio de cólulas efectoras, aumentar la eficiencia de las interacciones de ligando receptor de integrina estabilizará la sinapsis inmunitaria y mejorará las funciones efectoras. Las composiciones y métodos que incluyen los mimóticos mejoran: (1) el cebado de vacunas (incluyendo, de manera enunciativa, vacunas contra el cáncer); (2) la actividad citolítica de las terapias con cólulas adoptivas (incluyendo, de manera enunciativa, cólulas YdT, CTL, NK, iNKT); (3) las inmunoterapias (incluyendo, de manera enunciativa, estrategias de bloqueo para punto de comprobación negativo tales como anti-CTLA-4 y anti-PD-1); y (4) las terapias biológicas (incluyendo, de manera enunciativa, trastuzumab y rituxamab), con los cuales el mecanismo de acción incluye una citotoxicidad celular dependiente de anticuerpos (ADCC).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154554P | 2015-04-29 | 2015-04-29 | |
| PCT/US2016/029683 WO2016176400A2 (en) | 2015-04-29 | 2016-04-28 | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants |
| US15/140,711 US10342866B2 (en) | 2015-04-29 | 2016-04-28 | Compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013859A true MX2017013859A (es) | 2018-07-06 |
Family
ID=57198770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013859A MX2017013859A (es) | 2015-04-29 | 2016-04-28 | Composiciones novedosas y metodos para inmunoterapias que comprenden adyuvantes del agonistas del ligando receptor de integrina de molecula pequeña. |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US10342866B2 (es) |
| JP (2) | JP2018514562A (es) |
| KR (3) | KR20240052078A (es) |
| CN (1) | CN107820429B (es) |
| AU (1) | AU2016254034B2 (es) |
| CA (1) | CA2984316A1 (es) |
| IL (1) | IL255297B (es) |
| MX (1) | MX2017013859A (es) |
| SG (2) | SG10201911607YA (es) |
| WO (1) | WO2016176400A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11311619B2 (en) * | 2016-04-28 | 2022-04-26 | 7 Hills Pharma Inc. and Texas Heart Institute | Integrin activator vaccine compositions |
| SG10201911607YA (en) * | 2015-04-29 | 2020-01-30 | 7 Hills Interests Llc | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants |
| WO2018112364A1 (en) * | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating melanoma |
| WO2018112360A1 (en) * | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating cancer |
| CN114502192A (zh) * | 2019-08-16 | 2022-05-13 | 加利福尼亚大学董事会 | 涉及整合素的化学激活和靶向细胞免疫疗法的组合癌症疗法 |
| US20220118086A1 (en) * | 2020-09-10 | 2022-04-21 | 7 Hills Pharma LLC | Integrin agonists or activating compounds and methods for making and using same |
| WO2023018472A1 (en) * | 2021-08-10 | 2023-02-16 | Texas Heart Institute | Aminoaryl-integrin agonists compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA006505B1 (ru) | 2001-12-20 | 2005-12-29 | Лабораториос С.А.Л.В.А.Т.,С.А. | Производные карбамата 1-алкил-1-азониабицикло[2.2.2]октана и их применение в качестве антагонистов мускаринового рецептора |
| CN106075435A (zh) * | 2004-06-04 | 2016-11-09 | 健泰科生物技术公司 | 用于治疗多发性硬化的方法 |
| KR20080030023A (ko) * | 2005-07-26 | 2008-04-03 | 가부시키가이샤 시세이도 | 주름 방지·개선제 |
| CA2689408A1 (en) * | 2007-06-22 | 2008-12-31 | Bayer Schering Pharma Aktiengesellschaft | Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease |
| US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| WO2010143158A1 (en) * | 2009-06-12 | 2010-12-16 | Actelion Pharmaceuticals Ltd | Oxazole and thiazole derivatives as alx receptor agonists |
| ES2675914T3 (es) * | 2010-11-16 | 2018-07-13 | Texas Heart Institute | Agonistas que mejoran la unión de células que expresan integrina a receptores de integrina |
| CA2939512C (en) | 2014-02-12 | 2023-02-28 | 7 Hills Interests, Llc | Compositions and methods to improve the homing and grafting of hematopoetic stem cells |
| MX2017000082A (es) | 2014-07-01 | 2017-05-30 | 7 Hills Interests Llc | Composiciones y metodos para mejorar terapias con celulas adoptivas. |
| SG10201911607YA (en) * | 2015-04-29 | 2020-01-30 | 7 Hills Interests Llc | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants |
-
2016
- 2016-04-28 SG SG10201911607YA patent/SG10201911607YA/en unknown
- 2016-04-28 MX MX2017013859A patent/MX2017013859A/es unknown
- 2016-04-28 SG SG11201708846XA patent/SG11201708846XA/en unknown
- 2016-04-28 CN CN201680036891.3A patent/CN107820429B/zh active Active
- 2016-04-28 KR KR1020247011631A patent/KR20240052078A/ko active Application Filing
- 2016-04-28 KR KR1020177034574A patent/KR20170136651A/ko not_active IP Right Cessation
- 2016-04-28 KR KR1020247011632A patent/KR20240052079A/ko active Application Filing
- 2016-04-28 US US15/140,711 patent/US10342866B2/en active Active
- 2016-04-28 WO PCT/US2016/029683 patent/WO2016176400A2/en active Application Filing
- 2016-04-28 JP JP2017556837A patent/JP2018514562A/ja active Pending
- 2016-04-28 CA CA2984316A patent/CA2984316A1/en active Pending
- 2016-04-28 AU AU2016254034A patent/AU2016254034B2/en active Active
-
2017
- 2017-10-27 IL IL255297A patent/IL255297B/en unknown
-
2019
- 2019-04-25 US US16/394,277 patent/US10716849B2/en active Active
- 2019-04-25 US US16/394,270 patent/US10709780B2/en active Active
- 2019-07-19 US US16/516,907 patent/US10709781B2/en active Active
-
2021
- 2021-05-06 JP JP2021078488A patent/JP7244570B2/ja active Active
- 2021-06-29 US US17/362,512 patent/US20220001009A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2984316A1 (en) | 2016-11-03 |
| US20190343952A1 (en) | 2019-11-14 |
| SG11201708846XA (en) | 2017-11-29 |
| AU2016254034A1 (en) | 2017-12-14 |
| US10342866B2 (en) | 2019-07-09 |
| SG10201911607YA (en) | 2020-01-30 |
| KR20240052078A (ko) | 2024-04-22 |
| JP7244570B2 (ja) | 2023-03-22 |
| KR20240052079A (ko) | 2024-04-22 |
| US10709780B2 (en) | 2020-07-14 |
| US20220001009A1 (en) | 2022-01-06 |
| CN107820429A8 (zh) | 2018-06-01 |
| US10716849B2 (en) | 2020-07-21 |
| IL255297A0 (en) | 2017-12-31 |
| CN107820429B (zh) | 2022-08-16 |
| US20200054743A1 (en) | 2020-02-20 |
| US10709781B2 (en) | 2020-07-14 |
| WO2016176400A3 (en) | 2016-12-08 |
| US20190351052A1 (en) | 2019-11-21 |
| US20160339098A1 (en) | 2016-11-24 |
| CN107820429A (zh) | 2018-03-20 |
| KR20170136651A (ko) | 2017-12-11 |
| IL255297B (en) | 2021-10-31 |
| AU2016254034B2 (en) | 2021-11-04 |
| JP2021121602A (ja) | 2021-08-26 |
| WO2016176400A2 (en) | 2016-11-03 |
| JP2018514562A (ja) | 2018-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017013859A (es) | Composiciones novedosas y metodos para inmunoterapias que comprenden adyuvantes del agonistas del ligando receptor de integrina de molecula pequeña. | |
| MX2023007045A (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos. | |
| MX2023000818A (es) | Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos. | |
| PH12017500803A1 (en) | Anti-pd-1 antibodies | |
| AU2018253589A1 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
| MX2020010530A (es) | Anticuerpos humanizados contra cd269 (bcma). | |
| PH12018502400A1 (en) | Anti-tim-3 antibodies and methods of use thereof | |
| PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
| BR112019002687A2 (pt) | receptores de antígeno quimérico que direcionam bcma e métodos de uso dos mesmos | |
| WO2017011804A8 (en) | Engineered cells for adoptive cell therapy | |
| PH12017500190A1 (en) | An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use | |
| EP4265633A3 (en) | Compositions and methods for inhibition of lineage specific antigens | |
| SG10201809157VA (en) | Crispr-cas-related methods, compositions and components for cancer immunotherapy | |
| PH12018500363A1 (en) | Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof | |
| MX2022005955A (es) | Metodos y composiciones para terapia celular adoptiva. | |
| MX2018004503A (es) | Receptores de antigeno quimerico anti-cd30. | |
| MX2017000646A (es) | Celulas geneticamente modificadas para terapia celular adoptiva. | |
| MX2018009312A (es) | Celulas presentadoras de antigeno modificadas por ingenieria y usos de las mismas. | |
| SG10201808258SA (en) | Improved methods for manufacturing adoptive cell therapies | |
| MX2017005344A (es) | Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva. | |
| BR112016023523A2 (pt) | produtos de células t modificados em gene de composição definida | |
| MX2017003201A (es) | Inhibidores macrociclicos de las interacciones proteina/proteina de muerte programada 1 (pd-1)/pd-l1 y cd80(b7-1)/pd-l1. | |
| MX2018009228A (es) | Proteínas de unión a antigeno que se unen a pd-l1. | |
| MX2018006996A (es) | Composiciones y metodos mejorados para la entrega viral de neoepitopos y usos de estos. | |
| EP4295914A3 (en) | Genetically-engineered drug resistant t cells and methods of using the same |